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Background: Two Cancer and Leukemia Group B (CALGB) studies were utilized to determine the efficacy and
tolerability of paclitaxel (Taxol) in older patients with metastatic breast cancer.
Patients and methods: CALGB 9840 evaluated weekly paclitaxel (80 mg/m2) versus paclitaxel every 3 weeks (175
mg/m2); CALGB 9342 evaluated three doses of paclitaxel as follows: 175, 210 and 250 mg/m2 each over 3 h every 3
weeks. Of the 1048 patients, paclitaxel was used first line in 57%. The groups: (i) <55 years (45%), (ii) 55–64 years
(29%), and (iii) ‡65 years (26%).
Results: Tumor response was also similar among age groups. First-line therapy (P = 0.0001) and better performance
status (PS) (P = 0.018) were significantly related to higher response. Age did not significantly relate to overall survival
(OS) or progression-free survival (PFS). First-line therapy, better PS, estrogen receptor positive status and a fewer
number of metastatic sites were significantly related to improved OS and PFS. The grade ‡3 toxic effects that
increased linearly with age were leucopenia (P = 0.0099), granulocytopenia (P = 0.022), anorexia (P = 0.028), bilirubin
elevation (P = 0.0035) and neurotoxicity (P < 0.0001). Patients over 65 years receiving second-line therapy had the
shortest time to neurotoxicity.
Conclusions: Older women with breast cancer derive similar efficacy from treatment with paclitaxel as younger
women. Older women are at increased risk for specific toxic effects.
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introduction
Cancer is a disease of aging. The incidence of breast cancer
increases with increasing age and almost half of all new breast
cancers in the United States now occur in women aged ‡65
years [1, 2]. Systemic adjuvant chemotherapy in women
with early-stage breast cancer significantly improves both
relapse-free survival and overall survival (OS) for women aged
50–69 years, but there are less data for women aged ‡70 years.
Nevertheless, available data suggest that systemic adjuvant
chemotherapy may be significantly underused in older patients,
even though for many patients in this setting, chemotherapy
may improve survival [3]. Furthermore, chemotherapy can also
have significant palliative benefit in patients with metastatic
breast cancer [4]; however, when chemotherapy is administered
to older patients, dose reductions are frequently made that may
decrease efficacy [5]. These compromises are explained by the
perceived potential for increased chemotherapy-related toxic
effects in older patients. However, data from small trials and
retrospective analyses of larger trials suggest that older
women in good health tolerate chemotherapy, including
anthracycline-based regimens, with toxic effects profiles similar
to those of younger patients [6].
Paclitaxel is an integral part of the chemotherapy options for
women with breast cancer. It is used in both adjuvant treatment
and metastatic disease [6–9]. We conducted a retrospective
analysis of two large randomized trials of paclitaxel in the
metastatic setting to determine its efficacy and toxicity among
different age groups.
patients and methods
A retrospective review was undertaken of Cancer and Leukemia Group B
(CALGB) 9840 [8], which evaluated weekly paclitaxel (80 mg/m2 over 1 h)
versus paclitaxel every 3 weeks (175 mg/m2 over 3 h) and CALGB 9342 [9],
which compared three doses of paclitaxel: 175, 210, or 250 mg/m2 each
administered as a 3-h infusion every 3 weeks. CALGB 9342 initially enrolled
patients in the second-line setting but was amended to allow patients in the
first-line setting. CALGB 9840 accrued patients in both first- and
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second-line treatment. Prior taxane use was allowed if treatment was in the
adjuvant setting and had ceased at least 1 year earlier. Adequate hepatic,
renal and hematologic parameters were required. Patients receiving
trastuzumab (CALGB 9840 only) were required to have a normal baseline
left ventricular ejection fraction. Geriatric assessment was not part of the
original protocol and information of this type was not recorded. Informed
consent was obtained for all patients. Approval for this secondary analysis
of the data was obtained from the Cancer and Leukemia Group B Executive
Committee.
statistical analysis
The primary end point for the original trials was tumor response; the
secondary end points were OS, progression-free survival (PFS) and toxicity.
Tumor response was defined as complete or partial remission of breast
disease. OS was defined as the time from study entry until death due to any
cause. Surviving patients were censored at date of last contact. PFS was
defined as the time from study entry until first disease progression or death
without progression. Progression-free survivors were censored at the date
they were last known to be free from progression. Adverse events that
occurred at any time during the course of protocol therapy and that were
considered to be related to protocol treatment were graded according to
standard National Cancer Institute Expanded Common Toxicity Criteria
version 2. We used contingency tables to assess differences between two or
more proportions and the Cochran–Armitage test [10] to test for linear
trends over three proportions. Time to onset of a specific toxic event was
defined as the interval from study entry until estimated date of documented
grade 3, 4 or 5 toxicity, whichever grade occurred first. Because adverse
events were reported by time intervals rather than at exact dates of onset,
the onset date was estimated as the midpoint of the reporting interval.
Patients with grade 0–2 severities were censored at the date of last toxicity
assessment.
To test for an age effect on response, and OS and PFS, multivariate
logistic regression [11] and proportional hazards modeling [12],
respectively were used and adjusted for clinical variables of known
prognostic importance in metastatic breast cancer. Age was analyzed as
a categorical variable (<55 versus 55–64 versus ‡65) using two dummy
variables [13]. Other covariates were line of therapy (first versus second)
and estrogen receptive (ER) status (positive versus negative), each
analyzed as dichotomous variables; body mass index (BMI), defined from
the World Health Organization criteria as underweight (<18.5), normal
(18.5–24.9) and overweight (‡25) and analyzed as a categorical variable
(underweight versus normal versus overweight) using two dummy
variables; performance status and disease-free interval (DFI), measured
from date of diagnosis of original breast cancer to first recurrence, each
analyzed on a continuous scale; and number of sites of metastatic disease
at study entry, analyzed on a continuous scale using the square root
transformation. Time-to-event variables were estimated using the
Kaplan–Meier product limit method. Comparison of two or more
distributions used the log-rank test. Unless otherwise stated, all P-values
are two-sided. Statistical significance is defined as P £ 0.05. Data were
extracted from the CALGB database in August 2010.
The effect of trastuzumab was not included in this analysis. The data for
human epidermal growth factor receptor 2 (HER-2) status and hence
trastuzumab were first collected while CALGB 9840 was already accruing.
CALGB 9342 patients did not have HER-2 data collected and data were
missing for 290 of the 585 patients on CALGB 9840. When the CALGB
9840 study design was amended mid-trial, patients with HER-2-negative
tumors were randomized to paclitaxel with/without trastuzumab, while
those with HER-2-positive tumors were required to receive trastuzumab in
addition to paclitaxel. Additionally, the weekly dose schedule on CALGB
9840 was found to be significantly superior to the every 3-week schedule.
Therefore, 9840 had 10 unique patient subgroups identified by schedule
(weekly and q 3-weekly), HER-2 status (negative, positive and unknown)
and trastuzumab (no and yes). The complex relationship among these
variables makes direct comparisons difficult. The statistical analysis was
carried out by the CALGB Statistical Center.
results
The final sample consisted of all 1048 patients on CALGB
9342 and 9840 who began protocol treatment. The overall
median follow-up was 8.8 years (min = 8 days and max = 14
years). At the time of this analysis, 961 (92%) patients had
died, 83 were alive and in active follow-up, 1 was lost to
follow-up and 3 withdrew consent to be followed. Therapy
was received as first-line and second-line treatment by 599
and 449 patients, respectively. Patient demographics by age
and line of therapy are given in Table 1. Of the three age
categories, the largest proportion of patients were <55 years,
and the smallest proportion was ‡65 years. Regardless of age,
about two-thirds of the patients were overweight. Nearly all
patients had a CALGB performance score of zero or one.
Slightly more than half the patient sample had ER-positive
tumors. The median DFI was 2 years; one-third had a DFI
between 2 and 5 years, and the maximum was 37 years.
tumor response
Table 2 shows tumor response by age and line of therapy. The
incidence of tumor response was higher for patients on first-
line therapy (37%, 95% confidence interval [CI] = 33% to
41%) than for those on second-line therapy (24%, 95% CI =
20% to 29%); however, response did not differ by patient age
group within the first-line setting (36%, 40% and 35%) or
within the second-line setting (21%, 30% and 24%),
respectively. Results of multivariate logistic regression (Table
3) indicate that age was not associated with tumor response
(P = 0.097). First line of therapy (P = 0.0001) and better
performance status (P = 0.018) were significantly related to
a higher tumor response.
overall survival
First-line therapy, but not patient age, was associated with
superior OS. Table 4 shows the multivariate proportional
hazards model of selected prognostic variables on OS. After
adjusting for line of therapy and other variables, age was not
significantly related to OS (P = 0.73). First-line therapy (P <
0.0001), better performance score (P < 0.0001), tumoral ER-
positive status (P < 0.0001) and fewer metastatic sites (P =
0.0063) were all associated with survival benefit.
progression-free survival
As with OS, PFS was longer for patients receiving first-line
therapy than for those receiving second-line therapy. PFS did
not differ by age. Results of the multivariate proportional
hazards model (Table 4) on PFS show that age (P = 0.31) did
not significantly predict PFS. As with OS, first line of therapy
(P < 0.0001), better performance status (P = 0.0061),
positive INS> ER status (P = 0.0083) and lower number of
metastatic sites (P = 0.0080) were each predictive of
improved survival.
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grade ‡3 toxicity
The course of protocol therapy was similar across age groups
(Table 5). The median number of cycles delivered was six, six
and seven for patients aged <55, 55–64 and ‡65, respectively.
Incidence of at least one dose modification (20%, 23% and 24%)
and filgrastim use (6%, 5% and 7%) was similar by patient age.
The incidence by age of selected toxic effects of grade 3 or
higher severity that occurred any time during the treatment
course is shown in Table 5. Of note was the increased incidence
in neurotoxicity with increasing age cohort. Neurotoxic events
that were assessed and related to increasing age included
neurosensory (P < 0.0001), neuromotor (i.e. functioning;
P = 0.0002); neurocortical (i.e. somnolence, agitation;
P = 0.031) and neurocerebellar (i.e. coordination; P < 0.0001).
The first onset of serious neurotoxicity could occur at any time
over the entire treatment course. Neurotoxicity during first-line
treatment developed at a relatively slow rate with a similar
incidence at 18 weeks (i.e. after six cycles) among the three age
groups: 15% (<55 years), 11% (55–64 years) and 12% (‡65
years). Overall, patients receiving second-line treatment
experienced neurotoxicity sooner than patients receiving
first-line treatment with those on second-line therapy who were
‡65 years having the shortest time to neurotoxicity onset
compared with patients <65 (Figure 1). Of patients receiving
second-line therapy, age differences in neurotoxicity were first
observed after three cycles (9 weeks) when the incidence of
grade ‡3 neurotoxicity was 25% for the ‡65 group compared
with 10% and 15% for the two younger groups. By 18 weeks
(six cycles), the incidence had risen to 35% compared with 12%
and 20%, respectively.
We also observed age-related differences for hematologic
toxic effects with the incidence of leucopenia (P = 0.0099) and
granulocytopenia (P = 0.022) increasing with increasing age. In
contrast to the relatively constant rate of neurotoxicity onset,
the probability of developing myelosuppression was highest
after the first dose of therapy (3 weeks), and thereafter
plateaued, perhaps due to the use of hematopoietic growth
factors and/or dose reduction. Compared with patients on first-
line treatment, a considerably higher incidence of patients on
second-line treatment experienced hematologic toxicity during
the first cycle. Also, patients aged ‡65 who received second-line
treatment had the highest probability of experiencing either
hematologic toxicity.
The incidence of anorexia (P = 0.028), hyperbilirubinemia
(P = 0.0035) and malaise (P = 0.0028) were also highest in the
older patients. The incidence of hyperglycemia was not
increased in older patients.
discussion
In the current analysis, benefit from treatment was associated
with known prognostic factors, namely, performance status and
line of therapy, but not patient age. This is consistent with [14,
15] clinical trials in other solid tumors showing that older
patients derive the same benefit as younger patients. We
observed an increased incidence of several paclitaxel-related
toxic effects that were age related and more frequent in older
patients. This observation was most striking for several
neurotoxicities, including neurosensory, neuromotor and
Table 1. Patient demographics and pretreatment disease-related
variables by patient age
Variable Patient age (years)a
<55 55–64 ‡65
Total patients, n (%) 470 (100) 306 (100) 272 (100)
Study (%)
9342 44 44 46
9840 56 56 54
Line of therapy (%)
First 59 58 53
Second 41 42 47
Race (%)
White 68 77 86
Hispanic 3 3 3
Black 25 18 9
Oriental 11 1 1
Other/missing 2 1 1
Body mass index (%)
Underweight: <18.5 3 1 3
Normal: 18.5–24.9 33 29 30
Overweight: ‡25 62 69 65
Missing 2 1 2
Performance score (%)
0 50 45 43
1 43 47 49
2 5 5 7
3 1 1 0
Missing 2 2 1
ER status (%)
Negative 48 36 34
Positive 45 53 54
Missing 7 12 12
Disease-free interval (%)
£2 years 51 43 40
>2 and £5 years 36 34 36
>5 years 13 22 24
Missing 1 1 1
Number of met sites (%)
1–2 53 49 50
3–4 34 38 37
5–8 12 12 11
Missing 1 1 2
ER, estrogen receptor.
a137 patients (13%) ‡70 years.
Table 2. Tumor response (and 95% confidence interval [CI]) by patient
age and line of therapy
Line of therapy Age (years) Total
<55 55–64 ‡65
First line Assessable, N 272 173 144 589
Response, n (%) 98 (36) 70 (40) 50 (35) 218 (37)
95% CI (%) 30–42 33–48 27–43 33–41
Second line Assessable, N 192 128 127 447
Response, n (%) 41 (21) 38 (30) 30 (24) 109 (24)
95% CI (%) 16–28 22–38 17–32 20–29
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central nervous system (neurocortical and neurocerebellar)
side-effects and occurred in both the first- and second-line
settings. The onset of grade 3 or higher neurotoxicity occurred
sooner for patients on second-line treatment aged ‡65 years
than for younger second-line patients and for all patients on
first-line treatment.
The incidence of anorexia, malaise, hyperbilirubinemia and
hematologic toxicity (leucopenia and granulocytopenia) also
increased with increasing age but there was no age-related
difference in infection. As noted in other studies, and regardless
of age, the probability of developing hematologic toxicity was
greatest by the end of the first cycle of treatment. Compared
with patients on first-line treatment, proportionally more
patients on second-line treatment experienced hematologic
toxicity.
Paclitaxel is an important part of chemotherapy regimens
for a number of malignancies, particularly breast, lung and
gynecologic cancers. A prospective trial demonstrated
age-related differences in the pharmacokinetics of paclitaxel
but no significant adverse sequelae in terms of infectious
complications and hospitalization [13]. This trial analyzed
only the first cycle of treatment; therefore, cumulative
toxicity was not assessed. This report provides more
extensive data during an entire course of treatment. The
Gruppo Italiano di Oncologia Geriatrica (GIOGer) reported
a trial of weekly paclitaxel in elderly patients with breast
cancer. This prospective study included a baseline geriatric
assessment (GA). They demonstrated efficacy but an increase
in cardiovascular toxicity. The GA predicted a lower
probability of response and survival but not of toxicity. Their
analysis was likely limited by a relative small number of
patients (n = 46) [16].
Paclitaxel has rarely been associated with central nervous
system toxic effects [17]. It is difficult to assess whether the
increase noted in older patients is related to the chemotherapy
or less likely to the effect of short acting premedication
(dexamethasone and diphenhydramine). The neurosensory and
neuromotor toxic effects observed are particularly significant in
the older population and can potentially lead to loss of
mobility, increased falls and other disability. The increased risk
of neuropathy in older patients has not been consistently
observed in clinical trials [6, 15]. This may be due to excluding
patients with preexisting significant neuropathy or possibly lack
of reporting [17]. Age itself may not be a risk factor but the
additional comorbidities such as diabetes may be the
predisposing factor [18]. In view of this, older patients should
Table 3. Observed effect of age on tumor response (N = 913, tumor response = 33%)
Variable Comparison for OR, more :
less likely to respond
OR 95% confidence nterval
for OR
P-value
Age <55 : ‡65 1.03 0.72–1.48 0.097
55–64 : ‡65 1.38 0.94–2.02
Line of therapy First : Second 2.03 1.51–2.73 0.0001
DFI 1 : 5a 1.05 0.89–1.25 0.56
Performance score 1 : 2a 1.35 1.05–1.73 0.018
Tumoral ER status Negative : positive 1.01 0.75–1.35 0.98
Number of metastatic sites 2 : 5a 1.13 0.84–1.51 0.42
BMI Underweight : normal 1.35 0.43–4.24 0.26
Overweight : normal 1.26 0.92–1.71
BMI, body mass index; DFI, disease-free interval; ER, estrogen receptor; OR, odds ratio.
aThese variables were analyzed on a continuous scale; exact numbers are provided as examples for the OR.
Table 4. Observed effect of age on OS and PFS (N = 921; 91% OS and 95% PFS events)
Variable Comparison for HR, worse :
better
OS PFS
HR 95% CI for HR P-value HR 95% CI for HR P-value
Age <55 : ‡65 1.07 0.90–1.27 0.73 1.14 0.96–1.35 0.31
55–64 : ‡65 1.04 0.86–1.25 1.08 0.90–1.30
Line of therapy Second : First 1.85 1.61–2.13 <0.0001 1.52 1.32–1.74 <0.0001
DFI 1: 5a 1.02 0.93–1.11 0.69 1.01 0.93–1.11 0.75
Performance score 2 : 1a 1.37 1.22–1.55 <0.0001 1.18 1.05–1.32 0.0061
Tumoral ER status Negative : Positive 1.53 1.33–1.76 <0.0001 1.20 1.05–1.39 0.0083
Number of metastatic sites 5: 2a 1.22 1.06–1.40 0.0063 1.20 1.05–1.38 0.0080
BMI Normal : underweight 1.17 0.73–1.87 0.11 1.09 0.69–1.74 0.47
Normal : overweight 1.17 1.01–1.36 1.09 0.95–1.26
BMI, body mass index; CI, confidence interval; DFI, disease-free interval; ER, estrogen receptor; HR, hazard ratio; OR, odds ratio; OS, overall survival; PFS,
progression-free survival.
aThese variables were analyzed on a continuous scale; exact numbers are provided as examples for the HR.
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be closely monitored for neurotoxicity to minimize
complications.
The elderly patient may have a different spectrum of
dose-limiting toxicity than a younger patient and common
toxicity criteria as currently used may not be adequate to assess
adverse events in elderly patients. For example, assessment of
neuropathy in elders should include evaluation of functional
decline and falls. The reporting of toxicity in large clinical trials
should include a subset analysis of older patients. It is often
unclear whether a specific group of patients in a trial bears the
burden of toxicity. Most trials only report grade 3/4 toxicity;
grade 2 toxicity in an older patient often has clinical relevance.
It will help clinicians in decision making if they know the full
spectrum of toxicity. This combined analysis further confirms
that older patients who are eligible for clinical trials derive the
same benefit as younger patients and can be treated safely [19].
Paclitaxel has been shown to be tolerable in the elderly with
efficacy and safety [13, 16, 20]. These data suggest that
paclitaxel is as effective in carefully selected older as in younger
patients with metastatic breast cancer. The increased risk of
Table 5. Course of protocol treatment by patient age
Patient age (years) P-value
<55 55–64 ‡65
Number of patients treated, N (%) 470 (100) 306 (100) 272 (100)
Number of patients with Rx
and AE data, n (%)
465 (99) 302 (99) 270 (99)
Treatment
Number of cycles received,
Median (range)
6 (1–72) 6 (1–55) 7 (1–44) NS
Number of patients dose
modified, n (%) (95% CI
[%])
91 (20) (16–23) 68 (23) (18–28) 65 (24) (19–30) NS
If dose modified,
Number of cycles modified,
Median (range)
1 (1–8) 1 (1–9) 1 (1–3) NS
Number of Patients
received G-CSF, n (%) (95%
CI)
26 (6) (4–8) 16 (5) (3–8) 20 (7) (5–11) NS
If received G-CSF,
Number of cycles G-CSF,
Median (range)
2 (1–23) 2 (1–7) 1 (1–14) NS
Adverse events, grade 3 or higher (%) a
WBC 21 25 30 0.0099
Granulocytes 35 35 44 0.022
Anorexia 1 1 3 0.028
Bilirubin <1 1 3 0.0035
Neurosensory 17 18 28 <0.0001
Neuromotor 5 8 14 0.0002
Neurocortical 1 1 3 0.031
Neurocerebellar 0 1 3 <0.0001
Malaise 4 6 10 0.0028
Prothrombin time <1 3 0 0.013b
Eye <1 0 1 0.015b
NS, not significant (i.e. P-value >0.05); G-CSF, filgrastim.
aUnless otherwise indicated, P-value for tests on AE is from test for linear trend.
bFrom chi-square test for differences in proportions.
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Figure 1. CALGB 360701: second-line treatment. Second-line therapy
and time to grade 3 or more neurotoxicity.
original articles Annals of Oncology
636 | Lichtman et al. Volume 23 |No. 3 |March 2012
neurotoxicity in elders is of concern and older patients should
be closely monitored for this event.
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